

Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Urothelial Bladder Cancer — Part 3 of a Special 3-Part Edition

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Disitamab vedotin targets which of the following proteins?
 - a. Nectin-4
 - b. HER2
 - c. TROP2
 - d. FGFR
2. What was the approximate objective response rate observed in the cohort of patients receiving T-DXd for HER2-positive IHC 3+ urothelial carcinoma (UC) in the Phase II DESTINY-PanTumor02 trial?
 - a. 15%
 - b. 27%
 - c. 37%
 - d. 61%
3. What was the median overall survival observed in patients receiving T-DXd with nivolumab for HER2-high (IHC 3+/2+) advanced UC after chemotherapy in a Phase 1b/II clinical trial?
 - a. 5.5 months
 - b. 8 months
 - c. 11 months
 - d. 18 months
4. Which of the following adverse events is most commonly associated with enfortumab vedotin?
 - a. Bruising
 - b. Confusion
 - c. Skin reactions
 - d. Oral mucositis
5. Which of the following any-grade adverse events was most commonly reported with trastuzumab deruxtecan in the cohort of patients with UC in the Phase II DESTINY-PanTumor02 trial?
 - a. Nausea
 - b. Headache
 - c. Dermatitis
 - d. Hypotension